Supernus Pharmaceuticals (SUPN) Amortization - Intangibles (2019 - 2025)

Supernus Pharmaceuticals (SUPN) has 7 years of Amortization - Intangibles data on file, last reported at $24.6 million in Q4 2025.

• Amortization - Intangibles for Q4 2025 came in at $24.6 million, up 34.26% year-over-year; the trailing twelve-month figure through Dec 2025 was $89.5 million (up 14.72% YoY), and the FY2025 annual result was $89.5 million, up 14.74% from the prior year.
• Amortization - Intangibles rose to $24.6 million in Q4 2025 per SUPN's latest filing, from $24.3 million in the prior quarter.
• Over five years, Amortization - Intangibles peaked at $24.6 million in Q4 2025 and troughed at $5.9 million in Q2 2021.
• A 5-year average of $18.1 million and a median of $20.1 million in 2023 frame the typical range for Amortization - Intangibles.
• The sharpest annual moves came in 2021 and 2024: Amortization - Intangibles surged 376.37% in 2021, then declined 13.21% in 2024.
• A 5-year view of Amortization - Intangibles shows it stood at $12.0 million in 2021, then jumped by 72.23% to $20.7 million in 2022, then increased by 1.71% to $21.1 million in 2023, then declined by 13.21% to $18.3 million in 2024, then jumped by 34.26% to $24.6 million in 2025.
• Business Quant data shows SUPN's Amortization - Intangibles at $24.6 million in Q4 2025, $24.3 million in Q3 2025, and $20.8 million in Q2 2025.